Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.29 AUD -7.94% Market Closed
Market Cap: 112.9m AUD

Intrinsic Value

The intrinsic value of one PAR stock under the Base Case scenario is 0.16 AUD. Compared to the current market price of 0.29 AUD, Paradigm Biopharmaceuticals Ltd is Overvalued by 45%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PAR Intrinsic Value
0.16 AUD
Overvaluation 45%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Paradigm Biopharmaceuticals Ltd

PAR
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for PAR cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Paradigm Biopharmaceuticals Ltd
ASX:PAR
AU
Biotechnology
Market Cap
112.9m AUD
IPO
Aug 19, 2015
AU
Biotechnology
Market Cap
112.9m AUD
IPO
Aug 19, 2015
Price
AU$false
EPS
AU$false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about PAR?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Paradigm Biopharmaceuticals Ltd
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Paradigm Biopharmaceuticals Ltd

Current Assets 32.3m
Cash & Short-Term Investments 24.8m
Receivables 6.4m
Other Current Assets 1.1m
Non-Current Assets 3.1m
PP&E 118.2k
Intangibles 2.9m
Efficiency

Free Cash Flow Analysis
Paradigm Biopharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Paradigm Biopharmaceuticals Ltd

Revenue
5.7m AUD
Cost of Revenue
-27.7k AUD
Gross Profit
5.7m AUD
Operating Expenses
-21.3m AUD
Operating Income
-15.6m AUD
Other Expenses
30.5k AUD
Net Income
-15.6m AUD
Fundamental Scores

PAR Profitability Score
Profitability Due Diligence

Paradigm Biopharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Paradigm Biopharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

PAR Solvency Score
Solvency Due Diligence

Paradigm Biopharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Paradigm Biopharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PAR Price Targets Summary
Paradigm Biopharmaceuticals Ltd

Wall Street analysts forecast PAR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PAR is 0.82 AUD with a low forecast of 0.81 AUD and a high forecast of 0.84 AUD.

Lowest
Price Target
0.81 AUD
179% Upside
Average
Price Target
0.82 AUD
181% Upside
Highest
Price Target
0.84 AUD
190% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Paradigm Biopharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for PAR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PAR Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one PAR stock?

The intrinsic value of one PAR stock under the Base Case scenario is 0.16 AUD.

Is PAR stock undervalued or overvalued?

Compared to the current market price of 0.29 AUD, Paradigm Biopharmaceuticals Ltd is Overvalued by 45%.

Back to Top